Dr. Jack Cush Reviews the News and Journal articles from the past week on RheumNow. This weeks highlights includes insights on scleroderma, myositis, vasculitis and answers the question - does aggressive biologic treatment of psoriasis prevent future psoriatic arthritis?
A single center cohort study analyzed the outcome and survival of idiopathic inflammatory myositis (IIM) patients and showed good 5 and 10 year survival but showed significant declined 15-25 years post-diagnosis.
A multinational study of rheumatoid arthritis (RA) patients shows a variety of post-translationally modified anti-modified protein antibodies (AMPA). While AMPA differed in different ethnic populations, their levels correlated with total serum IgG.
Dr. John Cush RheumNow
3 years 7 months ago
Study of 21 Downs syndrome pts shows DS to be an autoimmunity-prone state, with a steady-state cytokinopathy, and evidence of hyperactivated CD4 T cells and ongoing activated B cells (CD11c+) - all contribute to a breach in immune tolerance. https://t.co/UUEByfBrqk https://t.co/ekq8AHYlxQ
Dr. John Cush RheumNow
3 years 7 months ago
GCA patients with AORTITIS proven by CTA or FDG-PET/CT have higher rates of relapse. Among 82 GCA pts, 78% positive on both CTA & PET. Relapse was seen in 70% in the CTA+/PET+ group & 29% in the CTA-/PET+ (p = 0.019). https://t.co/psA6hywouL https://t.co/WORiBd9Qli
Dr. John Cush RheumNow
3 years 7 months ago
New PMR Paradigm
Lessons from the clinic, brought to you by RheumNow Live. Join us on March 18 &19, 2023 in Dallas, TX
https://t.co/4umv0FvmsQ https://t.co/iFQGIHiIds
Dr. John Cush RheumNow
3 years 7 months ago
Does Biologic Treatment in Psoriasis Reduce the Risk of PsA?
Retrospective claims analysis shows that psoriasis patients treated with an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident PsA.
https://t.co/j73V7zMnkn https://t.co/EhGUXDNNlS
Dr. John Cush RheumNow
3 years 7 months ago
My Bum Knee
QD Clinic - Lessons from the clinic, brought to you by RhuemNow Live, March 18 &19, 2023 - Dallas, TX
https://t.co/nqBiAZsYGY https://t.co/MxhCbrWm3p
Dr. John Cush RheumNow
3 years 7 months ago
BRIDGE-PMR a proof-of-concept trial studied 1 dose of IV RTX in 47 PMR pts - at 1 yr, 52% RTX were in GC-free remission (compared to 21% given PBO). Eight (33%) patients in the placebo group and six (26%) in the rituximab group had adverse events https://t.co/yv8ezFN5BJ https://t.co/7FOOPbEIf3
Dr. John Cush RheumNow
3 years 7 months ago
Bullous pemphigoid is an autoimmune blistering Dz that may be seen with other hematologic dz - hemophilia A, hypereosinophilic syndrome, autoimmune thrombocytopenia, aplastic anemia, Heme malignancy (MDS, CLL, etc) https://t.co/i8WdA28hYP https://t.co/RsJMt9RTNl
A Medicare study shows that young adults with systemic lupus erythematosus (SLE) exhibit very high 30-day rehospitalization rates (36%) that are significantly higher than older SLE patients and age matched non-SLE patients.
Alopecia areata totalis (AT) and universalis (AU) are the most severe and difficult to treat forms of alopecia areata (AA). Yet a randomized controlled trial has shows that the combination of methotrexate (MTX) and low-dose prednisone can yield complete hair regrowth in nearly one-third of patients.
